Trial Profile
A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacokinetics
- Sponsors AbbVie
- 06 Dec 2021 Planned End Date changed from 29 Nov 2024 to 16 Nov 2021.
- 06 Dec 2021 Planned primary completion date changed from 29 Nov 2024 to 16 Nov 2021.
- 06 Dec 2021 Planned initiation date changed from 15 Nov 2022 to 15 Nov 2021.